Article
The impact of genetics on future drug discovery in schizophrenia.
Expert opinion on drug discovery - 1 Jul 2017
Matsumoto Mitsuyuki, Walton Noah M, Yamada Hiroshi, Kondo Yuji, Marek Gerard J, Tajinda Katsunori
Abstract excerpt
INTRODUCTION: Failures of investigational new drugs (INDs) for schizophrenia have left huge unmet medical needs for patients. Given the recent lackluster results, it is imperative that new drug discovery approaches (and resultant drug candidates) target pathophysiological alterations that are shared in specific, stratified patient populations that are selected based on pre-identified biological signatures. One...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
